Motus GI Holdings ROA 2016-2023 | MOTS
Current and historical return on assets (ROA) values for Motus GI Holdings (MOTS) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Motus GI Holdings ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2023-09-30 | $-0.01B | $0.01B | -112.00% |
| 2023-06-30 | $-0.02B | $0.01B | -108.47% |
| 2023-03-31 | $-0.02B | $0.01B | -107.46% |
| 2022-12-31 | $-0.02B | $0.02B | -96.20% |
| 2022-09-30 | $-0.02B | $0.02B | -91.95% |
| 2022-06-30 | $-0.02B | $0.02B | -82.47% |
| 2022-03-31 | $-0.02B | $0.02B | -74.77% |
| 2021-12-31 | $-0.03B | $0.03B | -90.43% |
| 2021-09-30 | $-0.03B | $0.03B | -88.50% |
| 2021-06-30 | $-0.02B | $0.03B | -84.21% |
| 2021-03-31 | $-0.02B | $0.03B | -87.62% |
| 2020-12-31 | $-0.02B | $0.02B | -76.77% |
| 2020-09-30 | $-0.02B | $0.03B | -78.50% |
| 2020-06-30 | $-0.02B | $0.02B | -80.73% |
| 2020-03-31 | $-0.02B | $0.03B | -94.12% |
| 2019-12-31 | $-0.02B | $0.03B | -97.87% |
| 2019-09-30 | $-0.02B | $0.03B | -108.24% |
| 2019-06-30 | $-0.02B | $0.01B | -133.33% |
| 2019-03-31 | $-0.02B | $0.02B | -116.67% |
| 2018-12-31 | $-0.02B | $0.02B | -117.33% |
| 2018-09-30 | $-0.02B | $0.01B | -131.15% |
| 2018-06-30 | $-0.02B | $0.02B | -122.03% |
| 2018-03-31 | $-0.02B | $0.02B | -161.90% |
| 2017-12-31 | $-0.01B | $0.01B | -247.62% |
| 2017-06-30 | $-0.01B | $0.00B | inf% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.001B | $0.000B |
| Motus GI Holdings, Inc. is a medical technology company. It focuses on the development and commercialization of the Pure-Vu(R) System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company also operates through subsidiaries in the U.S. and Israel. Motus GI Holdings, Inc. is based in FL, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GE HealthCare Technologies (GEHC) | United States | $39.304B | 21.86 |
| Inspire Medical Systems (INSP) | United States | $6.761B | 0.00 |
| 10x Genomics (TXG) | United States | $3.916B | 0.00 |
| Axonics (AXNX) | United States | $3.434B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $3.407B | 0.00 |
| Enovis (ENOV) | United States | $3.115B | 23.67 |
| Azenta (AZTA) | United States | $2.986B | 243.41 |
| Hims & Hers Health (HIMS) | United States | $2.832B | 0.00 |
| Olink Holding AB (publ) (OLK) | Sweden | $2.828B | 0.00 |
| Privia Health (PRVA) | United States | $2.177B | 96.58 |
| Schrodinger (SDGR) | United States | $1.847B | 0.00 |
| Phreesia (PHR) | United States | $1.283B | 0.00 |
| Omnicell (OMCL) | United States | $1.234B | 30.20 |
| Definitive Healthcare (DH) | United States | $0.835B | 0.00 |
| Standard BioTools (LAB) | United States | $0.804B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.620B | 0.00 |
| Talkspace (TALK) | United States | $0.540B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.332B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.317B | 0.00 |
| Clover Health Investments (CLOV) | United States | $0.315B | 0.00 |
| Pulmonx (LUNG) | United States | $0.288B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.195B | 0.00 |
| Augmedix (AUGX) | United States | $0.183B | 0.00 |
| American Well (AMWL) | United States | $0.161B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.156B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.132B | 0.00 |
| TruBridge (TBRG) | United States | $0.125B | 5.34 |
| Outset Medical (OM) | United States | $0.105B | 0.00 |
| 111 (YI) | China | $0.085B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.082B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.076B | 0.00 |
| Zepp Health (ZEPP) | China | $0.055B | 0.00 |
| HeartBeam (BEAT) | United States | $0.048B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.042B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.033B | 0.00 |
| Movano (MOVE) | United States | $0.027B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.024B | 0.00 |
| Cue Health (HLTH) | United States | $0.024B | 0.00 |
| ETAO (ETAO) | United States | $0.020B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.020B | 0.00 |
| CareCloud (CCLD) | United States | $0.019B | 0.00 |
| Akili (AKLI) | United States | $0.018B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.016B | 0.00 |
| Centogene (CNTG) | Germany | $0.013B | 0.00 |
| Biotricity (BTCY) | United States | $0.013B | 0.00 |
| Transgenomic (PRPO) | United States | $0.010B | 0.00 |
| Syra Health (SYRA) | United States | $0.007B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.006B | 0.00 |
| Zhongchao (ZCMD) | China | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |